Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

rmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage pre clinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate," "believe," "estimate," "expect," "expectation," "should," "would," "project," "plan," "predict," "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past res
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 On September ... sole exhibition focusing on medical design and manufacturing - ... the Shanghai World Expo Exhibition & Convention Center, bringing ... countries and regions to showcase their latest medical-grade raw ... now only one week remaining for free visitor pre-registration ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
... ImpactRx, the pioneer in measuring the impact ... Kjell Nygren, Ph.D. has joined the company as ... company,s position as a state-of-the-art provider of analytical ... the effectiveness of their promotional activities in driving ...
Cached Medicine Technology:New Test to Screen for Glaucoma Damage 2ImpactRx Names Kjell Nygren Vice President, Analytical Services 2
(Date:9/16/2014)... Lake Worth, FL (PRWEB) September 16, 2014 ... Millennium Treatment Group, they take care to make sure ... best for them. For some, this may include the ... new online therapy program which gives patients the opportunity ... Millennium Treatment Group can provide medical and clinical care ...
(Date:9/16/2014)... September 16, 2014 Aspen Advisors, a ... has been recognized for its high morale and ... “The Best Small Firms to Work For 2014.” ... with more than 10,000 consultants participating across all major ... satisfaction surveys were conducted, and firms were ranked in ...
(Date:9/16/2014)... cancer may one day be able to predict when ... and sexual functioning, thanks in part to new findings ... the American Society for Radiation Oncology,s 56th Annual Meeting ... from more than 17,000 surveys completed by men diagnosed ... urinary and sexual symptoms changed following each type of ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in ... hypertension association that works to find ways to prevent and ... that affects the functioning of the heart and can lead ... 2.8 years. , What:, Colorado PH in the Park ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News: Most Treatments for Blood Clots Appear Safe, Effective 2
... 3, 2008 A new study presented ... by researchers for Scientific,Food Solutions,( http://www.scientificfoodsolutions.com/pages/clinicals.html ) ... Vitamin C with,Bioperine(R), provides 275 percent faster ... Reece, President of Scientific Food Solutions said, ...
... the American Association for Dental Research,s (AADR) High School ... with the AADR,s 37th Annual Meeting & Exhibition at ... the High School for Health Professions, the Talented and ... School. The program includes a tour of Baylor College ...
... how to eat during seasons key to maintaining health, ... get bombarded on a,regular basis about health, diets and ... According to the Institute for Integrative Nutrition,the largest nutrition ... to maintaining health and wellness, regardless of which,diet you ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration and ... novel thermal energy called plasma for reversing the ... Food and Drug Administration (FDA),clearance to market a ... already cleared by the FDA for treating facial ...
... Campos Ramirez, 60, was sentenced to 10 years in ... defraud Medicare, Assistant Attorney General,Alice S. Fisher of the ... Southern District of Florida announced today. The scheme,represents the ... of the program., Campos was sentenced today in ...
... Ventas, Inc.,(NYSE: VTR ) ("Ventas" or the ... the Company at the Credit Suisse 2008 Global,Real Estate ... at 2:50 p.m.,Eastern Time., The presentation will be ... http://www.ventasreit.com . Any written materials,accompanying the presentation will ...
Cached Medicine News:Health News:Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Owner of Medicare Billing Service Sentenced to 10 Years In Prison For Role in $170 Million Medicare Fraud Scheme 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: